Levosimendan for low cardiac output: A pediatric experience

Journal of Intensive Care Medicine

Volumn 21, Issue 3, 2006, Pages 183-187

  Egan, Jonathan R ^a   Clarke, Andrew J B ^a   Williams, Stephen ^a   Cole, Andrew D ^b   Ayer, Julian ^a   Jacobe, Stephen ^a   Chard, Richard B ^a   Winlaw, David S ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b NONE

Author keywords

Congenital heart disease; Heart failure; Levosimendan; Pediatric

Indexed keywords

INOTROPIC AGENT; LACTIC ACID; LEVOSIMENDAN;

ADOLESCENT; ARTICLE; CARDIOPULMONARY BYPASS; CHILD; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DRUG SAFETY; FORWARD HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE PERFUSION; HEART RATE; HEART SURGERY; HUMAN; INFANT; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; MEAN ARTERIAL PRESSURE; MORTALITY; NEWBORN; OBSERVATIONAL STUDY; PEDIATRICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; HEART DEFECTS, CONGENITAL; HEMODYNAMIC PROCESSES; HUMANS; HYDRAZONES; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; PYRIDAZINES; RETROSPECTIVE STUDIES;

EID: 33646522956     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066606287039     Document Type: Article

References (12)

1. Haikala H, Nissinen E, Etemadzadeh E, et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol. 1995;25:794-801.
2. + channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249-259.
3. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-1432.
4. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
5. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107:81-86.
6. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102:2222-2227.
7. Luther YC, Schulze-Neick I, Stiller B, et al. Levosimendan-long-term inodilation in an infant with myocardial infarction. Z Kardiol. 2004;93:234-239.
8. Braun JP, Schneider M, Kastrup M, et al. Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. Eur J Cardiothorac Surg. 2004;26:228-230.
9. Turanlahti M, Boldt T, Palkama T, et al. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatr Crit Care Med. 2004;5:457-462.
10. SIMDAX clinical written summary [package insert]. OrionCorp, 2000. Espoo, Finland.
11. Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003;107:996-1002.
12. ++ -sensitizers for the treatment of heart failure. Curr Opin Crit Care. 2003;9:337-344.